At the IGTP TODAY

News

17/10/2018 - Research

New IGTP spin-off to develop gene therapy for Friedreich’s ataxia, a rare neurodegenerative disease

Biointaxis, the new spin-off company of the IGTP, was recently constituted. The company stems from research led by Dr Antoni Matilla-Dueñas together with Dr Ivelisse Sánchez of the Neurogenetics Group of the IGTP and has been created to increase translational research leading to treatments and new genomic technologies for rare neurological diseases with genetic causes. The first project the company is undertaking is the development of a gene therapy for Friedreich's Ataxia.

26/06/2018 - Research

Researchers describe the cause and neurodegenerative mechanisms of a new sub-type of ataxia

The Neurogenetics Research Group at the Germans Trias i Pujol Research Group, led by Dr Antoni Matilla has found the mutation and described the molecular mechanism that causes the sub-type of ataxia SCA37, which they first described in 2013. This find means that all the families with this alteration can be diagnosed before symptoms appear and that carriers can receive genetic counselling. It is also the first step on developing personalized therapies.